Leukotriene B4: Metabolism and Signal Transduction

doi:10.1006/abbi.2000.2168

Archives of Biochemistry and Biophysics

Volume 385, Issue 2, 15 January 2001, Pages 231-241

https://doi.org/10.1006/abbi.2000.2168 Get rights and content

Abstract

Leukotriene B₄ (LTB₄) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Enzymes involved in the biosynthesis and metabolism of LTB₄ have been cloned, and their properties are well understood. Two G-protein-coupled receptors (BLT1 and BLT2) have been cloned and characterized. BLT1 and BLT2 are high- and low-affinity LTB₄ receptors, respectively, and form a gene cluster in human and mouse. In this article recent findings on the metabolism of and the receptors for LTB₄ are reviewed. We also discuss briefly a coreceptor role of BLT in HIV infection, and ion channel modification by LTB₄.

References (107)

M. Minami et al.
J. Biol. Chem.
(1987)
P.J. Jakobsson et al.
J. Biol. Chem.
(1997)
J.F. Penrose et al.
J. Biol. Chem.
(1996)
N. Ohishi et al.
J. Biol. Chem.
(1990)
A. Sala et al.
J. Biol. Chem.
(1996)
T.G. Brock et al.
J. Biol. Chem.
(1995)
T.G. Brock et al.
J. Biol. Chem.
(1997)
T. Hirabayashi et al.
J. Biol. Chem.
(1999)
R.A. Lepley et al.
J. Biol. Chem.
(1996)
X.S. Chen et al.
J. Biol. Chem.
(1998)

P. Christmas et al.

J. Biol. Chem.

(1999)

A.M. Healy et al.

J. Biol. Chem.

(1999)

J.Z. Haeggström et al.

Biochem. Biophys. Res. Commun.

(1990)

M. Minami et al.

Biochem. Biophys. Res. Comm.

(1990)

L. Örning et al.

J. Biol. Chem.

(1991)

L. Örning et al.

J. Biol. Chem.

(1992)

M.J. Mueller et al.

J. Biol. Chem.

(1996)

I. Rybina et al.

J. Biol. Chem.

(1997)

F. Kull et al.

J. Biol. Chem.

(1999)

S. Shak et al.

J. Biol. Chem.

(1984)

Y. Kikuta et al.

J. Biol. Chem.

(1993)

Y. Kikuta et al.

FEBS Lett.

(1994)

T. Yokomizo et al.

J. Biol. Chem.

(1993)

T. Yokomizo et al.

J. Biol. Chem.

(1996)

C.B. Clish et al.

J. Biol. Chem.

(2000)

P. Wheelan et al.

Arch. Biochem. Biophys.

(1995)

Y. Tryselius et al.

Biochem. Biophys. Res. Commun.

(2000)

M. Kamohara et al.

J. Biol. Chem.

(2000)

I. Miki et al.

Biochem. Biophys. Res. Commun.

(1990)

D.M. Slipetz et al.

Eur. J. Pharmacol.

(1993)

C. Owman et al.

Genomics

(1996)

G.K.M. Akbar et al.

J. Biol. Chem.

(1996)

B.S. Khakh et al.

Trends Pharm. Sci.

(1998)

C. Owman et al.

Biochem. Biophys. Res. Commun.

(1997)

V. Martin et al.

J. Biol. Chem.

(1999)

Y. Boie et al.

Eur. J. Pharmacol.

(1999)

A. Toda et al.

Biochem. Biophys. Res. Commun.

(1999)

C.E. Heise et al.

J. Biol. Chem.

(2000)

J. Takasaki et al.

Biochem. Biophys. Res. Commun.

(2000)

A. Kuramasu et al.

J. Biol. Chem.

(1998)

B. Haribabu et al.

J. Biol. Chem.

(1999)

T. Akasaki et al.

J. Biol. Chem.

(1999)

B. Forman et al.

Cell

(1995)

S. Kliewer et al.

Cell

(1995)

P.R. Devchand et al.

J. Biol. Chem.

(1999)

F. Striggow et al.

Biochem. Biophys. Res. Commun.

(1997)

C.N. Serhan et al.

FASEB. J.

(1996)

T. Shimizu et al.

J. Neurochem.

(1990)

B. Samuelsson et al.

Science

(1987)

T. Yokomizo et al.

Nature

(1997)

Cited by (197)

Oxidative stress and metabolic syndrome in acne vulgaris: Pathogenetic connections and potential role of dietary supplements and phytochemicals
2023, Biomedicine and Pharmacotherapy
Acne vulgaris is a highly prevalent skin condition caused by androgen-induced elevated sebum secretion, abnormal keratinization, bacterial colonization, and inflammation. Current research indicates a link between acne vulgaris and the metabolic syndrome, a group of disorders that includes obesity, insulin resistance, hypertension, and dyslipidemia. This link is thought to be modulated by excessive concentrations of oxidative stress markers and chronic inflammation, which are included in the pathophysiological mechanisms shared by both conditions. Excessive generation of reactive oxygen species damages cellular components and initiates an inflammatory response, hence promoting the development of both disorders. The current narrative review focuses on the molecular implications of inflammatory, hormonal, and environmental factors in the acne-metabolic syndrome correlation. Furthermore, it outlines the current state of knowledge related to the phyto-therapeutic approach to these conditions as an adjuvant strategy to allopathic treatment, but future multicenter and larger-scale research studies are needed establish new algorithms to be included in the future management of patients with these conditions.
Recent advances in function and structure of two leukotriene B<inf>4</inf> receptors: BLT1 and BLT2
2022, Biochemical Pharmacology
Leukotriene B₄ (LTB₄) is generated by the enzymatic oxidation of arachidonic acid, which is then released from the cell membrane and acts as a potent activator of leukocytes and other inflammatory cells. Numerous studies have demonstrated the physiological and pathophysiological significance of this lipid in various diseases. LTB₄ exerts its activities by binding to its specific G protein-coupled receptors (GPCRs): BLT1 and BLT2. In mouse disease models, treatment with BLT1 antagonists or BLT1 gene ablation attenuated various diseases, including bronchial asthma, arthritis, and psoriasis, whereas BLT2 deficiency exacerbated several diseases in the skin, cornea, and small intestine. Therefore, BLT1 inhibitors and BLT2 activators could be beneficial for the treatment of several inflammatory and immune disorders. As a result, attractive compounds targeting LTB₄ receptors have been developed by several pharmaceutical companies. This review aims to understand the potential of BLT1 and BLT2 as therapeutic targets for the treatment of various inflammatory diseases. In addition, recent topics are discussed with major focuses on the structure and post-translational modifications of BLT1 and BLT2. Collectively, current evidence on modulating LTB₄ receptor functions provides new strategies for the treatment of various diseases.
Microarray analysis and PCR validation of genes associated with facultative parthenogenesis in Meleagris gallopavo (Turkey)
2022, Theriogenology
A cDNA microarray containing 43,661 differentially expressed genes was carried out on the blastoderm of fertilized and facultative parthenogenic turkey embryos at different hours of development. The total number of up-regulated (UR) and down-regulated (DR) genes at 0, 12, and 24 h of development were 725 and 1436, 942 and 599, and 589 and 1044, respectively. Common genes between 0 and 12 h, 12 and 24 h, and 0 and 24 h were 55, 67, and 110, respectively. The proportion of genes showing above 50-fold UR and DR at 0, 12, and 24 h of development were 2.0% and 1.5%, 0.5% and 1.2%, and 0.2% and 1.1%, respectively. Eight UR genes were validated (APOA1, THRAP3, ARL14EP, PSAP, MOG, MYBPC2, MTIF3 and EDG4) and relative expression of six of them was significantly higher (P ≤ 0.05) in parthenogenic embryos, while two genes showed non-significant (P ≥ 0.05) variation. The expression of BCL11A, PRP4B, TCP1, and TPI1 genes was significantly (P ≤ 0.05) DR in parthenotes in the micro-array study, while the TCP1 gene was up-regulated, and there was no variation in TPI1 gene expression in the PCR validation study. In conclusion, our findings demonstrate differential expression of a large number of genes in parthenotes at different stages of embryo development compared to fertilized embryos. Up-regulation of APOA1, MYBPC2, TCP1, and THRAP3 genes, suggest their crucial role in spontaneous facultative parthenogenic development in turkey birds.
Biological active ingredients of Astragali Radix and its mechanisms in treating cardiovascular and cerebrovascular diseases
2022, Phytomedicine
With the rising age of the global population, the incidence rate of cardiovascular and cerebrovascular diseases (CCVDs) is increasing, which causes serious public health burden. The efforts for new therapeutic approaches are still being sought since the treatment effects of existing therapies are not quite satisfactory. Chinese traditional medicine proved to be very efficient in the treatment of CCVDs. Well described and established in Chinese medicine, Astragali Radix, has been commonly administered in the prophylaxis and cure of CCVDs for thousands of years.
This review summarized the action mode and mechanisms of Astragali Radix phytochemicals on CCVDs, hoping to provide valuable information for the future application, development and improvement of Astragali Radix as well as CCVDs treatment.
A plenty of literature on biological active ingredients of Astragali Radix used for CCVDs treatment were retrieved from online electronic PubMed and Web of Science databases.
This review highlighted the effects of five main active components in Astragali Radix including astragaloside Ⅳ, cycloastragenol, astragalus polysaccharide, calycosin-7-O-β-d-glucoside, and calycosin on CCVDs. The mechanisms mainly involved anti-oxidative damage, anti-inflammatory, and antiapoptotic through signaling pathways such as PI3K/Akt, Nrf2/HO-1, and TLR4/NF-κB pathway. In addition, the majority active constituents in AR have no obvious toxic side effects.
The main active components of Astragali Radix, especially AS-IV, have been extensively summarized. It has been proved that Astragali Radix has obvious therapeutic effects on various CCVDs, including myocardial and cerebral ischemia, hypertension, atherosclerosis, cardiac hypertrophy, chronic heart failure. CAG possesses anti-ischemia activity without toxicity, indicating a worthy of further development. However, high-quality clinical and pharmacokinetic studies are required to validate the current studies.
Metabolism of natural forms of vitamin E and biological actions of vitamin E metabolites
2022, Free Radical Biology and Medicine
Natural forms of vitamin E comprise four tocopherols and four tocotrienols. During the last twenty years, there have been breakthroughs in our understanding of vitamin E metabolism and biological activities of vitamin E metabolites. Research has established that tocopherols and tocotrienols are metabolized via ω-hydroxylase (CYP4F2)-initiated side chain oxidation to form 13′-hydroxychromanol and 13′-carobyxychromanol (13′-COOH). 13′-COOHs are further metabolized via β-oxidation and sulfation to intermediate carboxychromanols, terminal metabolite carboxyethyl-hydroxychroman (CEHC), and sulfated analogs. Animal and human studies show that γ-, δ-tocopherol and tocotrienols are more extensively metabolized than α-tocopherol (αT), as indicated by higher formation of CEHCs and 13′-COOHs from non-αT forms than those from αT. 13′-COOHs are shown to be inhibitors of cyclooxygenase-1/-2 and 5-lipoxygenase and much stronger than CEHCs for these activities. 13′-COOHs inhibit cancer cell growth, modulate cellular lipids and activate peroxisome proliferator-activated receptor-γ and pregnane X receptor. Consistent with mechanistic findings, αT-13′-COOH or δTE-13′-COOH, respective metabolites of αT or δ-tocotrienol, show anti-inflammatory and cancer-preventive effects, modulates the gut microbiota and prevents β-amyloid formation in mice. Therefore, 13′-COOHs are a new class of bioactive compounds with anti-inflammatory and anti-cancer activities and potentially capable of modulating lipid and drug metabolism. Based on the existing evidence, this author proposes that metabolites may contribute to disease-preventing effects of γ-, δ-tocopherol and tocotrienols. The role of metabolites in αT's actions may be somewhat limited considering controlled metabolism of αT because of its association with tocopherol-transport protein and less catabolism by CYP4F2 than other vitamin E forms.
RNA adduction derived from electrophilic species in vitro and in vivo
2022, Chemico-Biological Interactions
Citation Excerpt :
Leukotriene A4 (LTA4, Scheme 7) is an epoxide metabolite known as an electrophilic species highly reactive to nucleophiles. The epoxide product can be transformed to the corresponding diol (leukotriene B4, LTB4) and glutathione conjugate (leukotriene C4, LTC4) catalyzed by epoxide hydrolase and glutathione S-transferase, respectively [88–91]. Reiber and co-workers first demonstrated significant reactivity of LTA4 to isolated nucleosides and nucleotides of RNAs in an alkaline solution [92].
RNA molecules are essential for cell function by not only serving as genetic materials, but also providing cells with structural support and catalytic functions. Due to nucleophilicity of nucleobases, RNA molecules can react with electrophilic species thus to be “adducted”. The electron-deficient agents potentially inducing adduction exist in a variety of natural sources including metabolic products of biomolecules. Although evident and readily detected in human tissue, RNA adduction remains poorly understood for their physiological and pathological function. In this article, we review a collection of exogenous and endogenous molecular species that participate in RNA adduction and elaborates on the chemical nature of their RNA adduction sites. Furthermore, we provide perspectives on the potential of RNA adducts as biomarkers of environmental insults. Finally, we project future investigations that are necessary for understanding the mechanisms of cellular toxicity of RNA adduction.

View all citing articles on Scopus

¹: To whom correspondence should be addressed. E-mail: [email protected].

²: Present address: Department of Biochemistry, Faculty of Medicine, Gunma University, Showamachi 3-39-22, Maebashi, Gunma 371-8511, Japan.

View full text

Regular ArticleLeukotriene B4: Metabolism and Signal Transduction

Abstract

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

Biochem. Biophys. Res. Comm.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

FEBS Lett.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Arch. Biochem. Biophys.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

Eur. J. Pharmacol.

Genomics

J. Biol. Chem.

Trends Pharm. Sci.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

Eur. J. Pharmacol.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Cell

Cell

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

FASEB. J.

J. Neurochem.

Science

Nature

Regular Article
Leukotriene B₄: Metabolism and Signal Transduction